Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
Finished Drug Prices
NA
1. 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitrile
2. Loxo-292
3. Serpercatinib
1. 2152628-33-4
2. Loxo-292
3. Retevmo
4. Selpercatinib [inn]
5. Cegm9ybngd
6. Selpercatinib [usan]
7. Ly3527723
8. Ret Inhibitor Loxo-292
9. Loxo292
10. 6-(2-hydroxy-2-methylpropoxy)-4-[6-[6-[(6-methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile
11. 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
12. Ly-3527723
13. 6-(2-hydroxy-2-methylpropoxy)-4-[6-[6-[(6-methoxy-3-pyridinyl)methyl]-3,6-diazabicyclo[3.1.1]hept-3-yl]-3-pyridinyl]pyrazolo[1,5-a]pyridine-3-carbonitrile
14. 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitrile
15. Pyrazolo(1,5-a)pyridine-3-carbonitrile, 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxy-3-pyridinyl)methyl)-3,6-diazabicyclo(3.1.1)hept-3-yl)-3-pyridinyl)-
16. Serpercatinib
17. Retevmo (tn)
18. Unii-cegm9ybngd
19. Selpercatinib [mi]
20. Selpercatinib [jan]
21. Loxo-292; Selpercatinib
22. Selpercatinib(loxo-292)
23. Selpercatinib [who-dd]
24. Chembl4559134
25. Schembl20071478
26. Selpercatinib (jan/usan/inn)
27. Gtpl10318
28. Bdbm296429
29. Dtxsid901026442
30. Selpercatinib [orange Book]
31. Bcp29047
32. Cld62833
33. Ex-a2859
34. Nsc818434
35. S8781
36. Who 10967
37. Zb1574
38. Us10112942, Example 163
39. Us10112942, Example 166
40. Us10112942, Example 183
41. Akos037649115
42. Nsc-818434
43. Ac-31588
44. Bs-16622
45. Loxo-292;loxo 292;loxo292
46. Selpercatinib (loxo-292, Arry-192)
47. Example 163 [wo2018071447a1]
48. Hy-114370
49. Cs-0084279
50. D11713
51. D77980
52. A929273
Molecular Weight | 525.6 g/mol |
---|---|
Molecular Formula | C29H31N7O3 |
XLogP3 | 2.5 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 8 |
Exact Mass | 525.24883788 g/mol |
Monoisotopic Mass | 525.24883788 g/mol |
Topological Polar Surface Area | 112 Ų |
Heavy Atom Count | 39 |
Formal Charge | 0 |
Complexity | 885 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 2 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Selpercatinib is indicated for the treatment of _RET_ fusion-positive non-small cell lung cancer in adult patients. Selpercatinib is also indicated for the systemic treatment of advanced or metastatic _RET_-mutant medullary thyroid cancer and for the systemic treatment of _RET_ fusion-positive radioactive iodine-refractory thyroid cancer in both adult and pediatric patients aged 12 and over. Selpercatinib is currently approved for these indications under an accelerated approval scheme and continued approval may be contingent on future confirmatory trials.
FDA Label
Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)
Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC)
- advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor
- advanced RET fusion-positive thyroid cancer who require systematic therapy following prior treatment
Selpercatinib exerts anti-tumour activity in specific cancers through inhibition of mutated forms of RET tyrosine kinases. Due to its increased specificity for RET over other tyrosine kinases, selpercatinib is thought to have an improved safety profile compared to other multi-kinase inhibitors. Despite this, selpercatinib treatment is associated with hepatotoxicity, hypertension, QT interval prolongation, hemorrhagic events, risk of impaired wound healing, and embryo-fetal toxicity; some patients may also exhibit hypersensitivity to selpercatinib.
L01EX22
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01E - Protein kinase inhibitors
L01EX - Other protein kinase inhibitors
L01EX22 - Selpercatinib
Absorption
In patients with locally advanced or metastatic solid tumours receiving 160 mg of selpercatinib twice daily, steady-state was achieved after approximately 7 days, with a Cmax of 2,980 (CV 53%) and AUC0-24h of 51,600 (CV 58%). The absolute bioavailability is between 60 and 82% (mean 73%), and the median tmax is two hours. Food has no apparent effect on the AUC or Cmax of selpercatinib. Patients with hepatic impairment display a concomitant increase in AUC0-INF for mild (7%), moderate (32%), and severe (77%) impairment.
Route of Elimination
Selpercatinib administered as a single 160 mg dose in healthy individuals was primarily recovered in feces (69%, 14% unchanged) and urine (24%, 12% unchanged).
Volume of Distribution
Selpercatinib has an apparent volume of distribution of 191 L; the volume of distribution increases with increasing body weight.
Clearance
Selpercatinib has an apparent clearance of 6L/h; the clearance increases with increasing body weight.
Selpercatinib is predominantly metabolized in the liver by CYP3A4.
Selpercatinib has a half-life of 32 hours in healthy individuals.
Rearranged during transfection (RET) is a transmembrane receptor tyrosine kinase containing extracellular, transmembrane, and intracellular domains whose activity is required for normal kidney and nervous system development. Constitutive RET activation is primarily achieved through chromosomal rearrangements producing 5' fusions of dimerizable domains to the 3' _RET_ tyrosine kinase domain, such as _KIF5B-RET_ and _CCDC6-RET_, resulting in constitutive dimerization and subsequent autophosphorylation. Constitutive activation leads to increased downstream signalling and is associated with tumour invasion, migration, and proliferation. Selpercatinib is a direct RET kinase inhibitor, exhibiting IC50 values between 0.92 and 67.8 nM depending on the exact _RET_ genotype. Information based on natural as well as induced resistance mutations and molecular modelling suggests that selpercatinib directly inhibits RET autophosphorylation by competing with ATP for binding. Various single amino acid mutations at position 810 inhibit selpercatinib binding without significantly altering ATP binding, potentially leading to treatment failures. Selpercatinib is also reported to inhibit other tyrosine kinase receptors, including VEGFR1, VEGFR3, FGFR1, FGFR2, and FGFR3, at clinically relevant concentrations. The significance of these effects is not well studied.
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Selpercatinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Selpercatinib, including repackagers and relabelers. The FDA regulates Selpercatinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Selpercatinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Selpercatinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Selpercatinib supplier is an individual or a company that provides Selpercatinib active pharmaceutical ingredient (API) or Selpercatinib finished formulations upon request. The Selpercatinib suppliers may include Selpercatinib API manufacturers, exporters, distributors and traders.
click here to find a list of Selpercatinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Selpercatinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Selpercatinib active pharmaceutical ingredient (API) in detail. Different forms of Selpercatinib DMFs exist exist since differing nations have different regulations, such as Selpercatinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Selpercatinib DMF submitted to regulatory agencies in the US is known as a USDMF. Selpercatinib USDMF includes data on Selpercatinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Selpercatinib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Selpercatinib suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Selpercatinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Selpercatinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Selpercatinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Selpercatinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Selpercatinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Selpercatinib suppliers with NDC on PharmaCompass.
Selpercatinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Selpercatinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Selpercatinib GMP manufacturer or Selpercatinib GMP API supplier for your needs.
A Selpercatinib CoA (Certificate of Analysis) is a formal document that attests to Selpercatinib's compliance with Selpercatinib specifications and serves as a tool for batch-level quality control.
Selpercatinib CoA mostly includes findings from lab analyses of a specific batch. For each Selpercatinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Selpercatinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Selpercatinib EP), Selpercatinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Selpercatinib USP).
LOOKING FOR A SUPPLIER?